Cite
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
MLA
Sculier, Delphine, et al. “Efficacy and Safety of Dolutegravir plus Emtricitabine versus Standard ART for the Maintenance of HIV-1 Suppression: 48-Week Results of the Factorial, Randomized, Non-Inferiority SIMPL’HIV Trial.” PLoS Medicine, vol. 17, no. 11, Nov. 2020, pp. 1–17. EBSCOhost, https://doi.org/10.1371/journal.pmed.1003421.
APA
Sculier, D., Wandeler, G., Yerly, S., Marinosci, A., Stoeckle, M., Bernasconi, E., Braun, D. L., Vernazza, P., Cavassini, M., Buzzi, M., Metzner, K. J., Decosterd, L. A., Günthard, H. F., Schmid, P., Limacher, A., Egger, M., Calmy, A., and the Swiss HIV Cohort Study (SHCS), & Swiss HIV Cohort Study (SHCS). (2020). Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL’HIV trial. PLoS Medicine, 17(11), 1–17. https://doi.org/10.1371/journal.pmed.1003421
Chicago
Sculier, Delphine, Gilles Wandeler, Sabine Yerly, Annalisa Marinosci, Marcel Stoeckle, Enos Bernasconi, Dominique L. Braun, et al. 2020. “Efficacy and Safety of Dolutegravir plus Emtricitabine versus Standard ART for the Maintenance of HIV-1 Suppression: 48-Week Results of the Factorial, Randomized, Non-Inferiority SIMPL’HIV Trial.” PLoS Medicine 17 (11): 1–17. doi:10.1371/journal.pmed.1003421.